Establishment of an HPLC method for the analysis of biapenem and its impurities

doi:10.5246/jcps.2011.02.022

Abstract

Abstract:

An HPLC method for routine quality control of biapenem was established. A Dikma Diamonsil C18 column (250 mm×4.6 mm, 5 µm) was used with diode array detection and single wavelength detection at 220 nm. The mobile phase was consisted of acetonitrile-0.1% triethylamine water (1:99, v/v). The liner range for biapenem quantification was 0.05-10.0 mg/mL (r²= 0.999). The LOD and LOQ of impurity were 4.8 ng (S/N = 3) and 18.5 ng (S/N = 10), respectively. Intra-day RSD of main impurity and total impurity were 1.84% and 3.37% (n = 3); inter-day RSD of main impurity and total impurity were 4.84% and 7.58% (n = 9). The test solution was stable when stored at 4 ºC for 6 h. The impurity peaks of biapenem can be identified by chromatographic spectral correlation analysis using high-performance liquid chromatography-diode array detection data from the quality control method by calculating correlation coefficients without reference standards. Two hydrolysis degradation products with relative retention times (RRTs) of 0.528 and 0.743, two dimers with RRTs of 1.062 and 2.817 were identified in the quality control chromatogram. It provides a new way to identify impurity peaks by the routine HPLC-UV method.

Key words: Biapenem, HPLC-DAD, Two-dimensional chromatographic spectral correlative map, Identification, Impurities

CLC Number:

R917

Supporting:

Nan Wang, Chun-Feng Li, Dou-Sheng Zhang, Chang-Qin Hu^*. Establishment of an HPLC method for the analysis of biapenem and its impurities [J]. , DOI: 10.5246/jcps.2011.02.022.

References

[1] Hu, C.Q. Sci. China Chem. 2010, 40, 679-687.
[2] Q3A (R2): Impurities in New Drug Substances, International Conference on Harmonization of Technical Requirements for the Registration of Pharmaceuticals for Human Use, Geneva. 2006, http://www.ich.org
[3] European Pharmacopoeia. 7th ed. Council of Europe, Strasbourg. 2010, 559.
[4] The United States Pharmacopoeia. 33th ed. US Pharmacopeial Convention, Rockville, MD. 2010, 187.
[5] China Pharmacopoeia Commission. Pharmacopoeia of the People's Republic of China. Part. II, Beijing: China Medical Science and Technology Press, 2010, Appendix 205.
[6] Nageswara, R.R; Nagaraju, V. J. Pharm. Biomed. Anal. 2003, 33, 335-377.
[7] Kovaleski, J.; Kraut, B.; Mattiuz, A.; Giangiulio, M.; Brobst, G.; Cagno, W.; Kulkarni, P.; Rauch T. Adv. Drug Deliv. Rev. 2007, 59, 56-63.
[8] Li, J.; Zhang, D.S.; Yao, S.C.; Hu. C.Q. Sci. Sin. Chim. 2010, 40, 77-785.
[9] Xia, M.; Hang, T.J.; Zhang, F.; Li, X.M.; Xu, X.Y. J. Pharm. Biomed. Anal. 2009, 49, 937-944.
[10] Prasada, R.K.V.V.; Rani, A.; Raghava, R.A.V.; Bharathi, C.H.; Ramesh, D.; Naidu, A. J. Pharm. Biomed. Anal. 2007, 43, 1476-1482.
[11] Bharathi, C.H.; Prasad, C.S.; Vijaya, B.D. J. Pharm Biomed. Anal. 2007, 43, 733-740.
[12] Li, W.; Hu, C.Q. J. Chromatogr. A. 2008, 1190, 141-149.
[13] Li, W.; Hu, C.Q.; Jin, S.H. Acta Pharm Sin. 2007, 42, 1292-1297.
[14] Ikeda, K.; Ikawa, K.; Ikeda, A.; Nishikawa, Y.; Morikawa, N. J. Chromatogr. B. 2006, 844, 148-152.
[15] Moffat, A.C.; Trafford, A.D.; Jee, R.D.; Graham, P. Analyst. 2000, 125, 1341-1351.
[16] Jenke, D.R.; William, B.; Lake, R. J. Liq. Chromatogr. Relal. Technol. 1996, 19, 719-736.
[17] Analytical Methods Committee. Analyst. 1988, 113, 1469-1471.
[18] Sajonz, P.; Natishan, T.K.; Wu, Y.; Williams, J.M.; Pipik, B.; DiMichele, L.; Novak, T.; Pitzenberger, S.; Dubost, D.; Almarrson, ö. J. Liq. Chromatogr. Relal. Technol. 2001, 24, 2999-3015.